Nanoparticle Therapy for Targeted Drug Delivery in Organ Transplantation

器官移植中靶向药物输送的纳米颗粒疗法

• 批准号: 9225201
• 负责人: SATISH N NADIG
• 金额: $ 19.57万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-04-01 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9225201
• 关键词: Acute; Address; Adoptive Transfer; Adverse effects; Allogenic; Allografting; Antigen Presentation; Area; Attenuated; Binding; Biological; Biomedical Engineering; C3bi; Cardiac; Caring; Chronic; Clinical; Complement; Complement 3d; Complement 3d Receptors; Complement Activation; Complement Receptor; Data; Deposition; Development; Devices; Disease; Dose; Drug Delivery Systems; Drug Targeting; Effector Cell; Encapsulated; Endothelial Cells; Eragrostis; Event; Future; Glare; Goals; Graft Survival; Histology; Homing; Human; Immune system; Immunity; Immunohistochemistry; Immunologics; Immunologist; Immunosuppression; Immunosuppressive Agents; In Vitro; Inbred BALB C Mice; Infection; Inflammatory; Lead; Legal patent; Life; Longevity; Malignant Neoplasms; Measures; Mechanics; Mediating; Mentors; Metabolic; Methods; Micelles; Modeling; Modern Medicine; Mus; Organ; Organ Survival; Organ Transplantation; Outcome; Patients; Perioperative; Pharmaceutical Preparations; Pharmacotherapy; Phenotype; Property; Publishing; Recombinants; Regulatory T-Lymphocyte; Reperfusion Injury; Reperfusion Therapy; Research Personnel; Risk; Savings; Science; Seminal; Serum; Side; Sirolimus; Skin; Solid; System; T-Cell Activation; T-Lymphocyte; Therapeutic; Therapeutic immunosuppression; Tissue Grafts; Transplant Recipients; Transplantation; Transplanted Organ Complication; Umbilical vein; Vascular Diseases; Vitronectin; Work; Wound Healing; allograft rejection; base; cell type; clinically relevant; clinically translatable; complement C3d,g; cytokine; design; design and construction; drug preservation; efficacy testing; experience; experimental study; fluorophore; genetic regulatory protein; heart allograft; imaging study; immunosuppressed; improved; in vivo; isoimmunity; nanoparticle; nanotherapy; novel; organ transplant rejection; prevent; public health relevance; receptor mediated endocytosis; response; targeted delivery; targeted treatment; therapeutic target; uptake; vascular smooth muscle cell proliferation

 DESCRIPTION (provided by applicant): Organ transplantation is an accepted therapy for various end-stage organ diseases. Systemic immunosuppression is required to prevent immunologic rejection in transplanted allografts. However, side- effects such as infections, cancers, and metabolic derangements are among the list of complications that organ transplant recipients suffer while on the necessary organ saving immunosuppressant medication. While significant advancements have been made with the design and efficacy of newer immunosuppressive medications, many carry heightened systemic risk profiles. In particular, rapamycin, has been shown to be an effective immunosuppressant, but carries an increased risk of infection, wound healing problems and metabolic side-effects1. Recent studies have shown that utilization of sub-therapeutic doses of rapamycin (insufficient to inhibit graft rejectin) combined with a systemic increase in ex-vivo expanded, adoptively transferred regulatory T cells (Treg) may prevent graft rejection2. These seminal studies suggest that combined low dose rapamycin with standard immunosuppressive care may prolong graft survival by inducing the recipient's immune system to `self-immunosuppress'. A potential way to further circumvent the systemic side-effects of rapamycin administration is to develop strategies to specifically deliver rapamycin directly to the grafted tissues. Many of the priming events that lead to the development of an alloimmune response have been shown to occur at the level of the graft3. Thus, while current practice utilizes systemic immunosuppression to modulate host immunity there is a growing appreciation that immune suppression at the graft level may have more profound effects on alloimmunity whilst sparing the recipient from the complications of systemic immunosuppression. Here, we propose to use novel graft targeting self-assembling micelle nanoparticles to attenuate both acute and chronic rejection. To facilitate graft targeting, we will conjugate these Targeted Rapamycin Micelles (TRaM) to soluble recombinant complement receptor 2 (CR2), a targeting moiety we have extensively characterized4. CR2 binds to long lived cleavage fragments of complement protein C3 (iC3b, C3dg, and C3d), which we have shown to deposit in cardiac allografts early post-transplantation as a response to ischemia- reperfusion injury, an unavoidable event in all solid organ transplants5. In addition to rapamycin loading and CR2 targeting moiety coating, micelles will contain near infrared (NIR) fluorophores for homing and tracking imaging studies. The feasibility of CR2 mediated targeting has previously been demonstrated and successful delivery of complement regulatory proteins utilizing this targeting moiety has been achieved6. By utilizing the novel targeting capabilities o CR2 we will be able to deliver rapamycin directly to the grafted organ. We hypothesize that rapamycin may be packaged within a biologically inert nanoparticle, tracked, targeted to, and released at the level of a transplanted allograft as a means for drug delivery and local immunosuppression.

 描述（由申请人提供）：器官移植是一种可接受的治疗各种终末期器官疾病的方法。需要全身免疫抑制来防止同种异体移植物的免疫排斥反应。然而，副作用，如感染，癌症和代谢紊乱是器官移植受者在使用必要的器官保存免疫抑制药物时遭受的并发症之一。虽然新的免疫抑制药物的设计和疗效取得了重大进展，但许多药物具有更高的全身风险。特别是雷帕霉素，已被证明是一种有效的免疫抑制剂，但携带感染，伤口愈合问题和代谢副作用的风险增加1。最近的研究表明，使用亚治疗剂量的雷帕霉素（不足以抑制移植排斥），结合体外扩增的过继转移调节性T细胞（Treg）的全身性增加，可以预防移植排斥2。这些开创性的研究表明，结合低剂量雷帕霉素与标准的免疫抑制护理可能会延长移植物存活诱导受体的免疫系统的“自我免疫抑制”。进一步规避雷帕霉素给药的全身副作用的一种潜在方法是开发将雷帕霉素直接特异性递送至移植组织的策略。许多导致同种异体免疫反应发展的引发事件已被证明发生在移植物水平3。因此，尽管目前的实践利用全身免疫抑制来调节宿主免疫，但越来越多的人认识到，移植物水平的免疫抑制可能对同种免疫具有更深远的影响，同时使受体免受全身免疫抑制的并发症。在这里，我们建议使用新的移植靶向自组装胶束纳米粒子，以减轻急性和慢性排斥反应。为了促进移植靶向，我们将 将这些靶向雷帕霉素胶束（TRaM）与可溶性重组补体受体2（CR 2）偶联，这是我们已广泛表征的靶向部分4。CR2与补体蛋白C3的长寿命裂解片段（iC 3b、C3 dg和C3 d）结合，我们已经证明，作为对缺血-再灌注损伤（所有实体器官移植中不可避免的事件）的响应，其在移植后早期存款在心脏同种异体移植物中5。除了雷帕霉素负载和CR2靶向部分涂层之外，胶束还将含有近红外（NIR）荧光团，用于归巢和跟踪成像研究。先前已经证明了CR2介导的靶向的可行性，并且已经证实了利用该靶向部分成功递送补体调节蛋白6。通过利用CR2的新靶向能力，我们将能够将雷帕霉素直接递送到移植器官。我们假设雷帕霉素可以包装在一个生物惰性纳米颗粒，跟踪，靶向，并在移植的同种异体移植物的水平上释放作为药物输送和局部免疫抑制的手段。